Advanced Proteome Therapeutics Corp.

Recent News

  • Advanced Proteome Therapeutics Expands Operations

    Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is expanding operations with a new hire and additional lab space.APTI is pleased to report that it has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility. The expansion is part of APTI's plan to monetize its antibody-drug conjugate...

    2021-11-23 10:48 AM EST
  • Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's site-selective conjugation in the rapidly growing field of radioimmunoconjugates (RICs). The collaboration...

    2021-10-04 11:14 AM EDT
  • Advanced Proteome Therapeutics Provides Update on COVID Program

    Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and preliminary testing were initiated. In fall of last year, the program was deprioritized in the...

    2021-08-24 9:45 AM EDT
  • Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

    Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors of APTI. His research has focused on biomarker...

    2021-07-21 8:30 AM EDT
  • Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

    Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.APTI is pleased to report that Dr. Ravi Chari is joining the Company's Scientific Advisory Board and Dr. Rajeshkumar Manian is joining as the lead organic chemist. Dr. Chari has over 30 years of...

    2021-06-09 1:40 PM EDT
  • Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement

    Burnaby, British Columbia--(Newsfile Corp. - April 13, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the "Private Placement") raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 per unit.Each unit consists of one...

    2021-04-13 5:12 PM EDT
  • Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company ("units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one...

    2021-03-11 1:38 PM EST
  • Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 1, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") announces that, subject to the approval of the TSX Venture Exchange (the "Exchange"), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant...

    2021-03-01 1:11 PM EST